Scarica l'app Stockscreener
21.58
1.01%
-0.23
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Rigel Pharmaceuticals Borsa (RIGL) Ultime notizie
Rigel Pharmaceuticals' (RIGL) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
Rigel's Fostamatinib Being Studied by National Institute of Health in Patients with Sickle Cell Disease - Marketscreener.com
Rigel's fostamatinib enters Phase 1 trial for sickle cell treatment - Investing.com
Rigel Pharmaceuticals enrolls first patient in Phase 1 study of fostamatinib - TipRanks
Rigel Pharmaceuticals Begins NIH-Sponsored Trial of Fostamatinib for Sickle Cell Disease Treatment - StockTitan
Cantor Fitzgerald Forecasts RIGL FY2025 Earnings - MarketBeat
JW Pharmaceutical gains approval for immune thrombocytopenia treatment TavalisseCHOSUNBIZ - 조선비즈
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Shares Sold by Assenagon Asset Management S.A. - MarketBeat
Long Term Trading Analysis for (RIGL) - Stock Traders Daily
KFDA approves immune thrombocytopenia treatment Tavalisse from Rigel PharmaceuticalsCHOSUNBIZ - 조선비즈
Assenagon Asset Management S.A. Sells 30,987 Shares of Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) - Defense World
Barclays PLC Grows Position in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) - MarketBeat
Short Interest in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Rises By 27.1% - MarketBeat
Wall Street Analysts Predict a 75.79% Upside in Rigel (RIGL): Here's What You Should Know - MSN
Retail Investors Bet On Anavex Lifesciences Stock To Outperform Novavax, Rigel Pharma In Q1 On Alzheimer’s Drug Buzz - MSN
Rigel (RIGL) Upgraded to Buy: Here's Why - MSN
Equities Analysts Set Expectations for RIGL Q4 Earnings - MarketBeat
Rigel Pharmaceuticals Seeks for Acquisitions -January 16, 2025 at 11:15 am EST - Marketscreener.com
Cantor Fitzgerald Has Positive View of RIGL FY2024 Earnings - MarketBeat
Rigel Pharmaceuticals' (RIGL) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat
Rigel forecasts revenue growth in 2025, reports Q4 sales - Investing.com India
RIGLRigel Pharmaceuticals Inc. (New) Latest Stock News & Market Updates - StockTitan
Rigel Pharmaceuticals sets 2025 sales outlook above estimates - MSN
Rigel forecasts revenue growth in 2025, reports Q4 sales By Investing.com - Investing.com South Africa
Rigel Provides Business Update and 2025 Outlook - PR Newswire
Rigel Pharma Revenue Soars as TAVALISSE Hits $100M Sales Milestone, Sets Ambitious 2025 Targets - StockTitan
(RIGL) Technical Data - Stock Traders Daily
Rigel announces R289 granted Orphan Drug designation by FDA for MDS - TipRanks
Rigel Pharmaceuticals Gets FDA Orphan-Drug Designation for R289 - MarketWatch
Rigel Announces R289 Granted Orphan Drug Designation by the FDA for MDS - PR Newswire
Rigel's MDS Drug R289 Receives FDA Orphan Drug Status, Boosting Market Exclusivity Potential - StockTitan
Rigel to Present at the 43rd Annual J.P. Morgan Healthcare Confe - GuruFocus.com
Rigel to Present at the 43rd Annual J.P. Morgan Healthcare Conference - PR Newswire
Jane Street Group LLC Lowers Holdings in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) - MarketBeat
Rigel Pharmaceuticals CEO to Present at J.P. Morgan Healthcare Conference 2025 - StockTitan
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - The Malaysian Reserve
Brokerages Set Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) PT at $36.20 - MarketBeat
Rigel Pharma expects to complete workforce reduction by Dec 15 - Reuters
Rigel Pharmaceuticals: Realizing The Promise Of Its Acquired Pipeline Agents (NASDAQ:RIGL) - Seeking Alpha
Rigel enrols first participant in Phase Ib/II AML treatment regimen trial - MSN
Rigel Pharmaceuticals (NASDAQ:RIGL) Shares Pass Above 200 Day Moving AverageShould You Sell? - MarketBeat
Lacklustre Performance Is Driving Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) 28% Price Drop - Simply Wall St
Rigel to Present at the Jefferies London Healthcare Conference - The Eastern Progress Online
(RIGL) Trading Signals - Stock Traders Daily
Rigel Pharmaceuticals' SWOT analysis: stock poised for growth amid challenges - Investing.com Australia
Recent 26% pullback isn't enough to hurt long-term Rigel Pharmaceuticals (NASDAQ:RIGL) shareholders, they're still up 50% over 1 year - Yahoo Finance
Thérapeutique Knight annonce l’approbation réglementaire de TAVALISSE® au Mexique - GlobeNewswire Inc.
Rigel Pharmaceuticals (NASDAQ:RIGL) shareholders are still up 50% over 1 year despite pulling back 26% in the past week - Simply Wall St
Immune Thrombocytopenia Purpura Market to Expand Significantly by 2034, States DelveInsight Report | Biotest, Argenx, Sanofi, Principia Biopharma, Rigel Pharma, Principia Biopharma, GlaxoSmithKline - The Globe and Mail
Rigel to Present at the 2024 Cantor Global Healthcare Conference - The Eastern Progress Online
Rigel Highlights Initial Data from Ongoing Phase 1b Study Evaluating R289 in LR-MDS at the 66th ASH Annual Meeting and Exposition - The Malaysian Reserve
Rigel Pharmaceuticals (NASDAQ:RIGL) Given "Buy" Rating at HC Wainwright - MarketBeat
0.98%
7.55%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):